pSILAC quantitative immunopeptidomics with Peptide-PRISM

downstream-application

pSILAC quantitative immunopeptidomics with Peptide-PRISM: downstream-application. Pulsed SILAC labelling combined with Peptide-PRISM de novo-based identification and MaxQuant quantification tracks how MAPK inhibition reshapes the melanoma…

Pulsed SILAC labelling combined with Peptide-PRISM de novo-based identification and MaxQuant quantification tracks how MAPK inhibition reshapes the melanoma immunopeptidome, revealing cryptic HLA peptides.

Kind	downstream-application
Deep learning	no
Acquisition	DDA
Application area	Immunopeptidomics / neoantigen

Data

What the papers describing this method trained it on and reported its results on, as each paper states it. A version is named only where the paper names one.

Deposited

• SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor-treated and resistant tumor cells (as deposited)

Paper describing it

• SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells (2025, Frontiers in Immunology, peer-reviewed)

Authors (9)

Melissa Bernhardt, Anne Rech, Marion Berthold, Melina Lappe, Jan-Niklas Herbel, Florian Erhard, Annette Paschen, Bastian Schilling, Andreas Schlosser

Seen in the charts

• Application areas
• Models and the authors behind them

Back to the full map